Sex: F
Vaccine: COVID19-2
Symptoms: Blood glucose, Hypoglycaemia, Intracardiac thrombus
Clinical narrative: blood clot in heart; blood sugar went real low; This spontaneous case was reported by a patient family member or friend and describes the occurrence of INTRACARDIAC THROMBUS (blood clot in heart) in a female patient of an unknown age who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. ASKU) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced INTRACARDIAC THROMBUS (blood clot in heart) (seriousness criteria death and medically significant) and HYPOGLYCAEMIA (blood sugar went real low). The patient died on an unknown date. The reported cause of death was blood clot in heart. It is unknown if an autopsy was performed. At the time of death, HYPOGLYCAEMIA (blood sugar went real low) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood glucose: went real low the day after the booster.     For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.   It was reported that patient's blood sugar went real low the day after the booster and patient recently died of a blood clot in the heart.  Reporter did not know the lot number and was unclear as to which dose precipitated these reported.  Treatment information was not provided.  Company comment: This spontaneous case concerns a female patient with no medical history provided, who experienced serious (death and medically significant) unexpected adverse event of special interest (AESI) of cardiac thrombosis, that occurred after the dose of the mRNA-1273 Bivalent.  Additional, non-serious, unexpected event of hypoglycemia occurred one day after the booster. The exact onset latency and dose number for the event of cardiac thrombosis was not provided. No further details regarding the event was provided. It is no known whether autopsy was performed. The benefit-risk relationship of mRNA-1273 is not affected by this report.   This case was linked to US-MODERNATX, INC.-MOD-2022-692686 (E2B Linked Report).; Sender's Comments: This spontaneous case concerns a female patient with no medical history provided, who experienced serious (death and medically significant) unexpected adverse event of special interest (AESI) of cardiac thrombosis, that occurred after the dose of the mRNA-1273 Bivalent.  Additional, non-serious, unexpected event of hypoglycemia occurred one day after the booster. The exact onset latency and dose number for the event of cardiac thrombosis was not provided. No further details regarding the event was provided. It is no known whether autopsy was performed. The benefit-risk relationship of mRNA-1273 is not affected by this report. US-MODERNATX, INC.-MOD-2022-692686:same reporter(reporter friends case); Reported Cause(s) of Death: blood clot in heart